Concourse Financial Group Securities, Inc. Anebulo Pharmaceuticals, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$1.77 - $3.08 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.9 - $3.12 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$2.34 - $3.0 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.71 - $3.17 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$2.15 - $3.49 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$2.15 - $3.49 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$2.06 - $2.98 $0 - $0
Q1 2023 May 15, 2023	BUY	$2.27 - $3.25 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.79 - $3.39 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$2.8 - $5.49 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$2.7 - $7.15 $0 - $0
Q1 2022 May 09, 2022	BUY	$6.0 - $7.7 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$5.84 - $7.3 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$6.55 - $7.77 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$6.58 - $8.95 $0 - $0

Others Institutions Holding ANEB

# of Institutions

Shares Held

7.34M

Call Options Held

Put Options Held

View Full List

About Anebulo Pharmaceuticals, Inc.

Ticker ANEB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,633,200
Market Cap $37.4M
Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...

More about ANEB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account